IVIg- præparater skal administreres med lavest mulige infusionshastighed og dosering hos patienter, der har risiko for at få akut nyresvigt eller tromboemboliske bivirkninger.
In patients at risk of acute renal failure or thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.